Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Novartis Files for Approval for LABA, LAMA Combination Treatment for COPD in Japan
November 9, 2012
- 1st-Half Settlements of Top 4 Wholesalers Suggest Recovery in Operating Profit Rates in Core Drug Business
November 9, 2012
- US FDA Approves Pfizer’s Novel RA Treatment Tofacitinib
November 9, 2012
- Four Companies Discontinue Marketing Atelec Generics Due to Halt in Supplies of Bulk Drug Substance
November 9, 2012
- Sales Down by 7.8% due to Slump of Long-Listed Drugs, Transfer of Marketing Rights for Cabaser: Kissei
November 8, 2012
- Nippon Shinyaku Confident about Achieving Target in Mid-Term Management Plan Backed by Steady Growth of New Products
November 8, 2012
- Ono: New Products Grow in 1st Half, Glactiv to Become Top-Selling Product
November 8, 2012
- Alfresa HD “Reached Some Degree of Agreement with Customers” Despite Non-Agreement Rate of Over 60% in 1st Half: President Ishiguro
November 8, 2012
- Kyorin Drops Development of DPP-4 Inhibitor as It Fails to Find Partner
November 8, 2012
- Otsuka Forms JV with Turkey’s No. 1 Drug Maker, Set to Launch Samsca in 2013
November 7, 2012
- Tolvaptan Suppresses Rate of Increase in Total Kidney Volume by 50%: Otsuka
November 7, 2012
- Eli Lilly Japan, Chugai to Terminate Comarketing Agreement for Evista
November 7, 2012
- Takeda to Buy Envoy of US to Reinforce Drug Discovery Prowess
November 7, 2012
- Ono Achieves Target Reduction of Sales Ratio of Long-Listed Drugs to Mid-50% Level: President Sagara
November 7, 2012
- Generic Sales Ratio Exceeds 80% for First Time in Interim Results: Nippon Chemiphar
November 6, 2012
- Abbott Splits into Two Companies; Research-Based Pharmaceuticals, Diversified Medical Products
November 6, 2012
- Abbott Japan Spins Off New Drug Biz, Establishes New Firm “AbbVie”
November 6, 2012
- Sawai’s Status Improved Within Mediceo by Utilizing ARs
November 6, 2012
- Asahi Kasei Pharma 1st Half Sales Show Significant Growth, Teribone May Exceed Peak Sales in 1st Year
November 6, 2012
- Astellas Logs Sales of 25.5 Bil. Yen in Oncology Sector, Investments Bearing Fruit: Pres. Hatanaka
November 5, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…